Inflammation and tumor progression: signaling pathways and targeted intervention
H Zhao, L Wu, G Yan, Y Chen, M Zhou… - Signal transduction and …, 2021 - nature.com
Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …
either promotes or suppresses tumor progression, potentially displaying opposing effects on …
Therapeutic cancer vaccines
M Saxena, SH van der Burg, CJM Melief… - Nature Reviews …, 2021 - nature.com
Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …
understanding of the breadth of tumour-associated antigens, the native immune response …
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
D Hirschhorn, S Budhu, L Kraehenbuehl, M Gigoux… - Cell, 2023 - cell.com
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
E Blass, PA Ott - Nature reviews Clinical oncology, 2021 - nature.com
Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …
cancers with the development and regulatory approval of various immune-checkpoint …
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and …
B cell function in the tumor microenvironment
SM Downs-Canner, J Meier, BG Vincent… - Annual review of …, 2022 - annualreviews.org
The tumor microenvironment (TME) is a heterogeneous, complex organization composed of
tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and …
tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and …
Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy
FG Herrera, C Ronet, M Ochoa de Olza, D Barras… - Cancer discovery, 2022 - AACR
Developing strategies to inflame tumors is critical for increasing response to immunotherapy.
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …
Designing cancer immunotherapies that engage T cells and NK cells
O Kyrysyuk, KW Wucherpfennig - Annual review of immunology, 2023 - annualreviews.org
T cells and natural killer (NK) cells have complementary roles in tumor immunity, and dual T
cell and NK cell attack thus offers opportunities to deepen the impact of immunotherapy …
cell and NK cell attack thus offers opportunities to deepen the impact of immunotherapy …
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among
exhausted CD8+ tumor-infiltrating lymphocytes, the terminally exhausted subset contributes …
exhausted CD8+ tumor-infiltrating lymphocytes, the terminally exhausted subset contributes …
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
S Pant, ZA Wainberg, CD Weekes, M Furqan… - Nature medicine, 2024 - nature.com
Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …